| ISRG |
Report |
Revenue |
BEAT |
pred ~$2.86B vs. cons $2.81B |
MEDIUM |
| ISRG |
Report |
da Vinci procedure growth (YoY) |
BEAT |
pred ~16.5% vs. cons ~15% |
HIGH |
| ISRG |
Report |
Non-GAAP EPS |
BEAT |
pred ~$2.56 vs. cons $2.48 |
MEDIUM |
| ISRG |
Guide |
FY2026 da Vinci procedure growth guide |
BETTER |
guide ~14.5-16% vs. cons ~15% (FY2026, prior range 13.5-15.5%) |
MEDIUM |
| ISRG |
Guide |
FY2026 non-GAAP gross margin guide |
UNCHANGED |
guide ~67.5-68.5% vs. cons ~68% (FY2026, tariff/memory drag embedded) |
MEDIUM |
| ISRG |
Guide |
da Vinci I&A revenue per procedure (recurring-revenue referendum) |
UNKNOWN |
pred ~$1,870-1,900 vs. cons ~$1,880 (Q2, instrument-life extension is the swing risk) |
LOW |
| ISRG |
Guide |
System placements (da Vinci + dV5 mix) |
BETTER |
pred ~430 da Vinci (~240 dV5) vs. cons ~415 (Q2, vs 395 yr-ago) |
MEDIUM |
| ISRG |
Return |
Day-1 residual (stock − beta × S&P 500) |
+6.0% |
— |
MEDIUM |
| ISRG |
Return |
5-day cumulative residual |
+3.5% (FADE) |
Washed-out sentiment (stock -33% YTD, multiple compressed to ~46x from ~72x) plus ISRG's historical beat-and-raise pattern set up a sharp relief pop on a clean procedure beat and raised full-year guide. But the rally partially fades over the week because the out-period math works against it: the instrument-life/reuse extensions structurally lower future I&A revenue-per-procedure, and tariff/memory/dV5-mix pressure caps gross-margin upside, so analysts trim out-year recurring-revenue and margin estimates even after a headline Q2 beat — leaving day-5 residual positive but below the day-1 spike. |
LOW |